Multicentre, prospective, randomised open-label blinded endpoint (PROBE) phase III study in stroke thrombolysis patients to compare tenecteplase and alteplase for an outcome of less disability at 3 months.
Phase of Trial: Phase III
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Tenecteplase (Primary) ; Alteplase
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Acronyms TASTE
- 19 Aug 2016 Planned End Date changed from 1 May 2017 to 31 Jul 2018.
- 18 Apr 2013 New trial record